[go: up one dir, main page]

GB202316857D0 - Cannabinoid-based formulation - Google Patents

Cannabinoid-based formulation

Info

Publication number
GB202316857D0
GB202316857D0 GBGB2316857.8A GB202316857A GB202316857D0 GB 202316857 D0 GB202316857 D0 GB 202316857D0 GB 202316857 A GB202316857 A GB 202316857A GB 202316857 D0 GB202316857 D0 GB 202316857D0
Authority
GB
United Kingdom
Prior art keywords
cannabinoid
based formulation
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB2316857.8A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
MRX Medical Ltd
Original Assignee
MRX Medical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by MRX Medical Ltd filed Critical MRX Medical Ltd
Priority to GBGB2316857.8A priority Critical patent/GB202316857D0/en
Publication of GB202316857D0 publication Critical patent/GB202316857D0/en
Priority to PCT/GB2024/052774 priority patent/WO2025093882A1/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Botany (AREA)
  • Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB2316857.8A 2023-11-03 2023-11-03 Cannabinoid-based formulation Ceased GB202316857D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GBGB2316857.8A GB202316857D0 (en) 2023-11-03 2023-11-03 Cannabinoid-based formulation
PCT/GB2024/052774 WO2025093882A1 (en) 2023-11-03 2024-11-01 Cannabinoid-based formulation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB2316857.8A GB202316857D0 (en) 2023-11-03 2023-11-03 Cannabinoid-based formulation

Publications (1)

Publication Number Publication Date
GB202316857D0 true GB202316857D0 (en) 2023-12-20

Family

ID=89164874

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB2316857.8A Ceased GB202316857D0 (en) 2023-11-03 2023-11-03 Cannabinoid-based formulation

Country Status (2)

Country Link
GB (1) GB202316857D0 (en)
WO (1) WO2025093882A1 (en)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL301006A (en) * 2016-03-16 2023-04-01 Buzzelet Development And Technologies Ltd Terpene-enriched cannabinoid composition
EP3687527A4 (en) * 2017-09-25 2021-05-26 Canopy Health Innovations COMPOSITIONS OF CANNABIDIOL, TETRAHYDROCANNABINOL, TERPENS AND FLAVONOIDS AND THEIR USES FOR TREATMENT OF INSOMNIA
CA3080434A1 (en) * 2017-10-30 2019-05-09 Endocanna Health, Inc. Graphical user interfaces for determining personalized endocannabinoid genotypes and associated recommendations
WO2022254338A1 (en) * 2021-06-04 2022-12-08 Buzzelet Development And Technologies Ltd. Compositions and methods for treating epilepsy and/or autism
WO2023172914A1 (en) * 2022-03-08 2023-09-14 Holistic Hemp Solutions, Inc. Tincture containing cannabinoids, method of using, and method of making the same

Also Published As

Publication number Publication date
WO2025093882A1 (en) 2025-05-08

Similar Documents

Publication Publication Date Title
GB202007546D0 (en) Formulation
IL319149A (en) Upadacitinib formulation
IL307849A (en) Sotorasib formulation
GB202102636D0 (en) Formulation
IL323027A (en) Formulation
GB202318884D0 (en) Formulation
GB202316857D0 (en) Cannabinoid-based formulation
CA3265602A1 (en) Aerosolisable formulation
GB202312814D0 (en) Formulation
GB202312220D0 (en) Formulation
GB202311622D0 (en) Formulation
GB202311439D0 (en) Formulation
IL317857A (en) Orellanine formulation
GB202308224D0 (en) Formulation
GB202306990D0 (en) Cannabinoid-based formulation
GB202306995D0 (en) Cannabinoid-based formulation
GB202307002D0 (en) Cannabinoid-based formulation
GB202307003D0 (en) Cannabinoid-based formulation
GB202303663D0 (en) Aerosolisable formulation
GB202218160D0 (en) Formulation
GB202217857D0 (en) Formulation
GB202217267D0 (en) Aerosolisable formulation
GB202217148D0 (en) Formulation
GB202216335D0 (en) Formulation
GB202211203D0 (en) Formulation

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)